Literature DB >> 10372731

Vasopressin receptors in human adrenal medulla and pheochromocytoma.

E Grazzini1, C Breton, S Derick, M Andres, D Raufaste, F Rickwaert, G Boccara, P Colson, N C Guérineau, C Serradeil-le Gal, G Guillon.   

Abstract

The nature of vasopressin (VP) receptors present in normal and tumoral human adrenal was investigated using various experimental approaches. Specific VP-binding sites were detected by autoradiography using [3H]arginine VP as a radioligand in adrenal cortex and medulla. The V1a receptor subtype was expressed in the two parts of the gland, as shown by pharmacological studies and RT-PCR experiments. By contrast, the V1b receptor subtype was only expressed in medullary chromaffin cells. This was confirmed by the characterization of V1b transcripts detected in adrenal medulla tissues. In pheochromocytoma, we also detected functional V1b receptors. These receptors triggered intracellular calcium mobilization from intracellular pools and were involved in catecholamine secretion. Binding experiments performed on pheochromocytoma plasma membrane preparations also revealed V1a vasopressin-binding sites, whose roles and cellular localization have not yet been determined. RT-PCR experiments confirmed these data; 100% and 80% of the five tumors tested exhibited V1a and V1b transcripts, respectively. Perifusion experiments also demonstrated that some pheochromocytomas may secrete large amounts of VP. Our findings imply that VP locally secreted by human adrenal medulla may regulate adrenal function by acting on V1a or V1b receptors. More interestingly, we demonstrate that one pheochromocytoma oversecretes VP. In this particular case, this may contribute to the increase in blood pressure observed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10372731     DOI: 10.1210/jcem.84.6.5775

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla.

Authors:  Stephanie M J Fliedner; Jan Breza; Richard Kvetnansky; James F Powers; Arthur S Tischler; Robert Wesley; Maria Merino; Hendrik Lehnert; Karel Pacak
Journal:  Cell Tissue Res       Date:  2010-04-30       Impact factor: 5.249

2.  Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.

Authors:  Miriam Andrés; Miguel Trueba; Gilles Guillon
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

3.  Vasopressin regulates the growth of the biliary epithelium in polycystic liver disease.

Authors:  Romina Mancinelli; Antonio Franchitto; Shannon Glaser; Antonella Vetuschi; Julie Venter; Roberta Sferra; Luigi Pannarale; Francesca Olivero; Guido Carpino; Gianfranco Alpini; Paolo Onori; Eugenio Gaudio
Journal:  Lab Invest       Date:  2016-08-29       Impact factor: 5.662

Review 4.  Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management.

Authors:  Graeme Eisenhofer; Graham Rivers; Alejandro L Rosas; Zena Quezado; William M Manger; Karel Pacak
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

5.  Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome.

Authors:  Umer Saleem; Mahyar Khaleghi; Nils G Morgenthaler; Andreas Bergmann; Joachim Struck; Thomas H Mosley; Iftikhar J Kullo
Journal:  J Clin Endocrinol Metab       Date:  2009-04-14       Impact factor: 5.958

6.  Increased levels of copeptin before clinical diagnosis of preeclampsia.

Authors:  Edwina H Yeung; Aiyi Liu; James L Mills; Cuilin Zhang; Tuija Männistö; Zhaohui Lu; Michael Y Tsai; Pauline Mendola
Journal:  Hypertension       Date:  2014-09-15       Impact factor: 10.190

Review 7.  The vasopressin Avpr1b receptor: molecular and pharmacological studies.

Authors:  Ja Roper; A-M O'Carroll; Ws Young; Sj Lolait
Journal:  Stress       Date:  2010-09-09       Impact factor: 3.493

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.